Navigation path

Pharmaceuticals - Union Register

  

Register of orphan medicinal products


GRANTED  

Product information

Autologous dendritic cells pulsed with tumour antigen-derived synthetic peptides (MAGE-1, HER-2, AIM-2, TRP-2, gp-100, and interleukin-13 receptor alpha)

EU orphan designation number: EU/3/14/1247   
Active ingredient: Autologous dendritic cells pulsed with tumour antigen-derived synthetic peptides (MAGE-1, HER-2, AIM-2, TRP-2, gp-100, and interleukin-13 receptor alpha)
Indication: Treatment of glioma
Sponsor: Diamond ROC EOOD
Bul. Gen. Totleben 53-55, Office 311, Kriva Reka, Sofia 1606, България

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
21/02/2014 Orphan designation EMA/OD/174/13 (2014)1222 of 19/02/2014
18/03/2019 Transfer of orphan designation EMA/OD/0000003818 (2019)2146 of 14/03/2019